March 21, 2018 10:03 AM EDTUpdated 10:51 AM

Proteostasis pulls stock offering following Kerrisdale short report; Cidara issues supplemental PhII rezafungin data

John Carroll

Editor & Founder

→ Hours after the company came under assault by the hit squad at Kerrisdale Capital, Proteostasis Therapeutics $PTI yanked a planned offering of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Proteostasis pulls stock offering following Kerrisdale short report; Cidara issues supplemental PhII rezafungin data

John Carroll

Editor & Founder

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Pro­teosta­sis pulls stock of­fer­ing fol­low­ing Ker­ris­dale short re­port; Cidara is­sues sup­ple­men­tal PhII reza­fun­gin da­ta

John Carroll

Editor & Founder

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Proteostasis pulls stock offering following Kerrisdale short report; Cidara issues supplemental PhII rezafungin data

Trump names Johns Hopkins researcher Marty Makary to lead the FDA

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?